statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the United...

Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression

Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report)s stock had its "buy" rating reaffirmed by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They...

Syros Pharmaceuticals (NASDAQ:SYRS) Rating Reiterated by HC Wainwright

Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced the grant of a...

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

For the last three days, A.I.dvisor has detected that SYRS's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Syros Pharmaceuticals (SYRS, $5.04) Aroon Indicator entered a Downtrend on April 01, 2024.

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Syros Pharmaceuticals (SYRS Research Report), with a pric...

Buy Rating Affirmed for Syros Pharmaceuticals Amid Promising Clinical Trials and Strategic Study Designs

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Get Free Report) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 1,740,000 shares, an...

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 31.8% in March

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS - Free Report) - Equities research analysts at Brookline Capital Management issued their FY2028 earnings per share (EPS) estimates for shares of Syros...

Brookline Capital Management Comments on Syros Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:SYRS)

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS  Free Report)  Research analysts at Brookline Capital Management raised their Q1 2024 earnings estimates for Syros Pharmaceuticals in a research...

Syros Pharmaceuticals, Inc. to Post Q1 2024 Earnings of ($0.74) Per Share, Brookline Capital Management Forecasts (NASDAQ:SYRS)

StockNews.com upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS  Free Report) from a sell rating to a hold rating in a research note released on Thursday.
Syros Pharmaceuticals Stock...

Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded by StockNews.com to "Hold"

This price move could be a signal that SYRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

Syros Pharmaceuticals (SYRS, $5.36) price may climb as it broke lower Bollinger Band on Mar 28, 2024

Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.

Volume	89,636.00
52-Wk High	$8.17
52-Wk Low	$2.09

SYRS Syros Pharmaceuticals Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals